Advertisement

Reactions Weekly

, Volume 1778, Issue 1, pp 99–99 | Cite as

Brigatinib/cetuximab/osimertinib

Chemotherapy resistance secondary to C797S mutation in cis with T790M: case report
Case report
  • 1 Downloads

Reference

  1. Wang X, et al. EP1.01-29 Lung Adenocarcinoma Harboring EGFR-19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy. Journal of Thoracic Oncology 14 (Suppl.): S922-S923 abstr. EP1.01-29, No. 10, Oct 2019. Available from: URL: https://www.sciencedirect.com/science/article/pii/S1556086419326851?via%3Dihub [abstract] - China

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations